Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803058 · ClinicalTrials.gov registry record · Phase 2
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
A Phase 2 study of Kidney Transplantation, sponsored by ITB-Med.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT04803058 is a Phase 2 study of Kidney Transplantation that is active but no longer recruiting, run by ITB-Med. The registered enrollment target is 18 participants, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04803058, a Phase 2 study of Kidney Transplantation, is active but no longer recruiting, sponsored by ITB-Med.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Conditions Studied
Interventions
- BIOLOGICAL TCD601
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Other
- Samsung Medical University - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803058
The ClinicalTrials.gov registry entry for NCT04803058 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (93% lower). The listed sponsor is ITB-Med, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which TCD601 is the first listed.
NCT04803058 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Minnesota, Other.
Frequently Asked Questions
What is clinical trial NCT04803058 about?
NCT04803058 is a clinical study titled "A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)". The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
What is the current status of trial NCT04803058?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2022-12-14. Estimated completion is 2030-03.
What conditions does trial NCT04803058 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT04803058?
The interventions under investigation include: TCD601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04803058?
This trial is sponsored by ITB-Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04803058 being conducted?
This trial has 3 study locations across Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
RECRUITING · Phase 2
-
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
COMPLETED · Phase 2
-
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
COMPLETED · Phase 2
-
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.